{"doi":"10.1017/cts.2022.401","title":"Leukotriene inhibitors with dexamethasone show promise in the prevention of death in COVID-19 patients with low oxygen saturations","abstract":"Abstract Introduction: COVID-19 is a major health threat around the world causing hundreds of millions of infections and millions of deaths. There is a pressing global need for effective therapies. We hypothesized that leukotriene inhibitors (LTIs), that have been shown to lower IL6 and IL8 levels, may have a protective effect in patients with COVID-19. Methods: In this retrospective controlled cohort study, we compared death rates in COVID-19 patients who were taking a LTI with those who were not taking an LTI. We used the Department of Veterans Affairs (VA) Corporate Data Warehouse (CDW) to create a cohort of COVID-19-positive patients and tracked their use of LTIs between November 1, 2019 and November 11, 2021. Results: Of the 1,677,595 cohort of patients tested for COVID-19, 189,195 patients tested positive for COVID-19. Forty thousand seven hundred one were admitted. 38,184 had an oxygen requirement and 1214 were taking an LTI. The use of dexamethasone plus a LTI in hospital showed a survival advantage of 13.5% (CI: 0.23%–26.7%; p < 0.01) in patients presenting with a minimal O 2 Sat of 50% or less. For patients with an O 2 Sat of <60 and <50% if they were on LTIs as outpatients, continuing the LTI led to a 14.4% and 22.25 survival advantage if they were continued on the medication as inpatients. Conclusions: When combined dexamethasone and LTIs provided a mortality benefit in COVID-19 patients presenting with an O 2 saturations <50%. The LTI cohort had lower markers of inflammation and cytokine storm.","journal":"Journal of Clinical and Translational Science","year":2022,"id":286328,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9668,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":962463,"name":"Skyler Resendez","orcid":"0000-0002-0422-2335","position":1,"is_corresponding":false},{"id":669233,"name":"Sarah Mullin","orcid":"0000-0002-5246-2202","position":2,"is_corresponding":false},{"id":484463,"name":"Bruce R. Troen","orcid":"0000-0002-3699-0021","position":3,"is_corresponding":false},{"id":739647,"name":"Manoj J. Mammen","orcid":"0000-0003-0343-3234","position":4,"is_corresponding":false},{"id":965256,"name":"Shirley Chang","orcid":"0000-0002-3329-5314","position":5,"is_corresponding":false},{"id":965257,"name":"Gillian Franklin","orcid":"0000-0001-6536-9843","position":6,"is_corresponding":false},{"id":962925,"name":"Wilmon McCray","orcid":null,"position":7,"is_corresponding":false},{"id":965258,"name":"Steven H. Brown","orcid":"0000-0001-6103-1845","position":8,"is_corresponding":false},{"id":545624,"name":"Peter L. Elkin","orcid":"0000-0001-9616-6811","position":0,"is_corresponding":true}],"reference_count":37,"raw_metadata":null,"created_at":"2026-07-19T00:29:48.841035Z","pmid":"35836784","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}